288 related articles for article (PubMed ID: 35634306)
41.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
42. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
43. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
[TBL] [Abstract][Full Text] [Related]
44. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis.
Singh S; Long JP; Tchakarov A; Dong Y; Yee C; Lin JS
JCI Insight; 2022 Dec; ():. PubMed ID: 36472921
[TBL] [Abstract][Full Text] [Related]
45. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
46. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Lauss M; Donia M; Svane IM; Jönsson G
Clin Cancer Res; 2022 May; 28(9):1751-1758. PubMed ID: 34965949
[TBL] [Abstract][Full Text] [Related]
47. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
48. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
49. Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.
Edmonds NL; Gradecki SE; Katyal P; Lynch KT; Stowman AM; Gru AA; Engelhard VH; Slingluff CL; Mauldin IS
Oncoimmunology; 2023; 12(1):2164476. PubMed ID: 36632563
[TBL] [Abstract][Full Text] [Related]
50. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.
Sakimura C; Tanaka H; Okuno T; Hiramatsu S; Muguruma K; Hirakawa K; Wanibuchi H; Ohira M
J Surg Res; 2017 Jul; 215():74-82. PubMed ID: 28688665
[TBL] [Abstract][Full Text] [Related]
51. Immune signatures in cutaneous melanoma correlate with survival independently of immunotherapy treatment.
Johansson PA; Hayward NK; Pritchard AL
Pigment Cell Melanoma Res; 2023 Mar; 36(2):246-251. PubMed ID: 36617535
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
53. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
[TBL] [Abstract][Full Text] [Related]
54. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
Zhou L; Xu B; Liu Y; Wang Z
Oncoimmunology; 2021 May; 10(1):1915574. PubMed ID: 34104539
[TBL] [Abstract][Full Text] [Related]
55. B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication.
Kinker GS; Vitiello GAF; Ferreira WAS; Chaves AS; Cordeiro de Lima VC; Medina TDS
Front Cell Dev Biol; 2021; 9():678127. PubMed ID: 34164398
[TBL] [Abstract][Full Text] [Related]
56. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
57. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
[TBL] [Abstract][Full Text] [Related]
58. Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma.
Nie Y; Fan H; Li J; Lei X; Zhang T; Wang Y; Mao Z; Tao K; Song W
FASEB J; 2022 Nov; 36(11):e22586. PubMed ID: 36190431
[TBL] [Abstract][Full Text] [Related]
59. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
60. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
